Clinical Trial Update: ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 ASCEND trial evaluating the safety and tolerability of Ionis' antisense therapy ION337 for Dravet syndrome; trial status is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome

Drugs mentioned

• ION337

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Dravet Syndrome | Phase 1, Phase 2 | Status: RECRUITING